

Application No. 09/965,697
Response dated August 18, 2006
Reply to Office Action dated April 18, 2006

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A multiple inducible gene regulation system comprising a plurality of individually operable gene regulation systems wherein:
 - a) each individually operable gene regulation system comprises:
 - i) one or more polynucleotides encoding a receptor complex comprising:
 - A) a DNA binding domain;
 - B) a ligand binding domain; and
 - C) a transactivation domain;
 - ii) a ligand;
 - iii) a polynucleotide comprising:
 - A) an exogenous or endogenous polynucleotide; and
 - B) a response element;
 - wherein:
 - A) the exogenous or endogenous polynucleotide is operatively linked to the response element; and
 - B) binding of the DNA binding domain to the response element in the presence or absence of the ligand results in activation or suppression of the exogenous or endogenous polynucleotide;
 - C) the ligand binding domain comprises a ligand binding domain from a nuclear steroid receptor; and
 - b) each individually operable gene regulation system is orthogonal to the other individually operable gene modulation system present in the multiple inducible gene modulation system.
2. (Currently amended) The multiple inducible gene regulation system of claim 1, wherein each operable gene regulation system comprises
 - a)
 - i) a first gene expression cassette comprising a polynucleotide that encodes a polypeptide comprising a transactivation domain, a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and a nuclear steroid receptor ligand binding domain,
 - ii) a ligand, and
 - iii) a second gene expression cassette comprising: A) a response element recognized by the DNA-binding domain of the encoded polypeptide of the first gene

Application No. 09/965,697

Response dated August 18, 2006

Reply to Office Action dated April 18, 2006

- expression cassette; B) a promoter that is activated by the transactivation domain of the encoded polypeptide of the first gene expression cassette; and C) a gene whose expression is to be modulated;
- b) i) a first gene expression cassette comprising a polynucleotide that encodes a polypeptide comprising a transactivation domain, a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and a nuclear steroid receptor ligand binding domain,
- ii) a second nuclear steroid receptor ligand binding domain selected from the group consisting of a vertebrate retinoid X receptor ligand binding domain, an invertebrate retinoid X receptor ligand binding domain, an ultraspiracle protein ligand binding domain, and a chimeric ligand binding domain comprising two polypeptide fragments, wherein the first polypeptide fragment is from a vertebrate retinoid X receptor ligand binding domain, an invertebrate retinoid X receptor ligand binding domain, or an ultraspiracle protein ligand binding domain, and the second polypeptide fragment is from a different vertebrate retinoid X receptor ligand binding domain, invertebrate retinoid X receptor ligand binding domain, or ultraspiracle protein ligand binding domain,
- iii) a ligand, and
- iv) a second gene expression cassette comprising: A) a response element recognized by the DNA-binding domain of the encoded polypeptide of the first gene expression cassette; B) a promoter that is activated by the transactivation domain of the encoded polypeptide of the first gene expression cassette; and C) a gene whose expression is to be modulated; or
- c) i) a first gene expression cassette comprising a polynucleotide that encodes a first polypeptide comprising a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated and a nuclear steroid receptor ligand binding domain,
- ii) a second gene expression cassette comprising a polynucleotide that encodes a second polypeptide comprising a transactivation domain and a nuclear steroid receptor ligand binding domain,
- iii) a ligand, and
- iv) a third gene expression cassette comprising: A) a response element recognized by the DNA-binding domain of the first polypeptide of the first gene expression cassette; B) a promoter that is activated by the transactivation domain of

Application No. 09/965,697
Response dated August 18, 2006
Reply to Office Action dated April 18, 2006

the second polypeptide of the second gene expression cassette; and C) a gene whose expression is to be modulated,

wherein one of the nuclear steroid receptor ligand binding domains of c)i) or c)ii) is a Group H nuclear steroid receptor ligand binding domain.

3. (Original) A virus comprising the multiple gene regulation system of claim 1.
4. (Original) A cell comprising the multiple gene regulation system of claim 1.
5. (Withdrawn) A transgenic organism comprising one or more cells of claim 4.
6. (Currently amended) The multiple inducible gene regulation system of claim 1, wherein one or more of the polynucleotides encoding a receptor complex encodes a nuclear steroid receptor complex.
7. (Original) The multiple inducible gene regulation system of claim 1, wherein one or more of the polynucleotides encoding a receptor complex encodes a non-mammalian receptor complex.
8. (Original) The multiple inducible gene regulation system of claim 6, wherein the receptor complex is an ecdysone receptor complex.
9. (Currently amended) A multiple inducible gene regulation system which comprises a plurality of individually operable gene regulation systems wherein:
 - a) each individually operable gene regulation system comprises:
 - i) one or more receptor complexes, each comprising:
 - A) a DNA binding domain;
 - B) a ligand binding domain; and
 - C) a transactivation domain;
 - ii) a ligand;
 - iii) a polynucleotide comprising:
 - A) an exogenous or endogenous gene; and
 - B) a response element;wherein:
 - A) the exogenous or endogenous gene is under the control of the response element; and
 - B) binding of the DNA binding domain to the response element in the presence or the absence of the ligand results in activation or suppression of the gene;
 - C) the ligand binding domain comprises a ligand binding domain from a nuclear steroid receptor; and
 - b) each individually operable gene regulation system is orthogonal to the other individually operable gene regulation systems present in the multiple inducible gene regulation system.
10. (Currently amended) The multiple inducible gene regulation system of claim 9, wherein each operable gene regulation system comprises

Application No. 09/965,697

Response dated August 18, 2006

Reply to Office Action dated April 18, 2006

- a)
 - i) a polypeptide comprising a transactivation domain, a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and a nuclear steroid receptor ligand binding domain,
 - ii) a ligand, and
 - iii) a gene expression cassette comprising: A) a response element recognized by the DNA-binding domain of the polypeptide of a)i); B) a promoter that is activated by the transactivation domain of the polypeptide of a)i); and C) a gene whose expression is to be modulated;
- b)
 - i) a polypeptide comprising a transactivation domain, a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and a nuclear steroid receptor ligand binding domain,
 - ii) a second nuclear receptor ligand binding domain selected from the group consisting of a vertebrate retinoid X receptor ligand binding domain, an invertebrate retinoid X receptor ligand binding domain, an ultraspiracle protein ligand binding domain, and a chimeric ligand binding domain comprising two polypeptide fragments, wherein the first polypeptide fragment is from a vertebrate retinoid X receptor ligand binding domain, an invertebrate retinoid X receptor ligand binding domain, or an ultraspiracle protein ligand binding domain, and the second polypeptide fragment is from a different vertebrate retinoid X receptor ligand binding domain, invertebrate retinoid X receptor ligand binding domain, or ultraspiracle protein ligand binding domain,
 - iii) a ligand, and
 - iv) a gene expression cassette comprising: A) a response element recognized by the DNA-binding domain of the polypeptide of b)i); B) a promoter that is activated by the transactivation domain of the polypeptide of b)i); and C) a gene whose expression is to be modulated; or
- c)
 - i) a first polypeptide comprising a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated and a nuclear steroid receptor ligand binding domain,
 - ii) a second polypeptide comprising a transactivation domain and a nuclear steroid receptor ligand binding domain,
 - iii) a ligand, and
 - iv) a gene expression cassette comprising: A) a response element recognized by the DNA-binding domain of the first polypeptide of c)i); B) a promoter that is

Application No. 09/965,697
Response dated August 18, 2006
Reply to Office Action dated April 18, 2006

activated by the transactivation domain of the second polypeptide of c)ii); and C) a gene whose expression is to be modulated, wherein one of the nuclear steroid receptor ligand binding domains of c)i) or c)ii) is a Group H nuclear steroid receptor ligand binding domain.

11. (Original) A virus comprising the multiple gene regulation system of claim 9.
12. (Original) A cell comprising the multiple gene regulation system of claim 9.
13. (Withdrawn) A transgenic organism comprising one or more cells of claim 12.
14. (Original) The multiple inducible gene regulation system of claim 9, wherein one or more of the receptor complexes is a Group H receptor complex.
15. (Original) The multiple inducible gene regulation system of claim 14, wherein the Group H receptor complex is an ecdysone receptor complex.
16. (Currently amended) A method to develop a multiple gene regulation system comprising the steps of:

- a) ~~preparing~~defining a set of ~~diversely modified ligands, wherein each ligand is modified by step-wise based on incremental~~ pharmacophore element changes;
- b) preparing a first set of receptor polypeptides, wherein each receptor polypeptide comprises a ligand binding domain from a nuclear steroid receptor that is:
 - i) naturally occurring;
 - ii) modified by deletion, insertion, or mutation;
 - iii) chimeric;
 - iv) synthetic; or
 - v) a combination thereof;
- c) optionally, introducing the receptor polypeptides into a cell;
- d) ~~querying, screening~~ the receptor polypeptides either in the cell of c) or *in vitro*, with the set of ~~diversely modified ligands~~ for gene modulation, or ligand binding domain binding, or both;
- e) tabulating the magnitude of gene modulation and/or binding for each ligand and receptor polypeptide combination to determining the orthogonality of the receptor polypeptide/ligand combinations;
- f) ~~to define~~identifying a subset of ligands ~~from the screen of step d)~~ with diverse gene modulation properties;
- g) optionally repeating steps a)-fe) using a modified set of ligands and a modified set of receptor polypeptides;
- hg) preparing a second set of receptor polypeptides, wherein each receptor polypeptide comprises a DNA binding domain that is:

Application No. 09/965,697
Response dated August 18, 2006
Reply to Office Action dated April 18, 2006

- i) naturally occurring;
 - ii) modified by deletion, insertion, or mutation;
 - iii) chimeric;
 - iv) synthetic; or
 - v) a combination thereof;
- ih) preparing a set of DNA constructs comprising an exogenous or endogenous gene and response elements which are:
- i) naturally occurring;
 - ii) modified by deletion, insertion, or mutation;
 - iii) chimeric;
 - iv) synthetic; or
 - v) a combination thereof;
- ii) cloning the first set of receptor polypeptides and the second set of receptor polypeptides and the DNA constructs and then introducing the clones into a cell;
- kj) assaying the cell for coreactivity to the ligands identified in step fe);
- lk) selecting an orthogonal set of ligands, ligand binding domains, DNA binding domains, and response elements based upon the results of steps fe) and kj) to comprise the multiple inducible gene regulation system.
17. (Cancelled)
18. (Previously presented) The method of claim 16, wherein one or more of the receptor polypeptides is a non-mammalian receptor polypeptide.
19. (Currently amended) The method of claim 16, wherein one or more of the nuclear steroid receptor polypeptides is a group H nuclear receptor polypeptides.
20. (Currently amended) The method of claim 16, wherein one or more of the nuclear steroid receptor polypeptides is an ecdysone receptor polypeptides.